Pharmaceuticals and biotechnology
Definition
Companies whose SEC Standard Industrial Classification code falls in 2833 to 2836, as EDGAR assigns them.
Q2 2026 against Q1 2026
- Reported value
- $667bn
- +$71.9bn on the quarter before
- Managers listing any
- 67
- +0 on the quarter before
- Stocks listed
- 330
- +4 on the quarter before
- Buyers
- 4,063
- manager-stock pairs opening or adding
- Sellers
- 3,620
- manager-stock pairs trimming or exiting
value over 8 quartersNet buying actions by quarter: +247 · +212 · +247 · +224 · +219 · +968 · +649 · +443
See it in the heatmap, ranked by breadth →
Managers listing any counts distinct comparable managers. Buyers and sellers count actions by comparable managers, once for each stock a manager moved in. Value moves with prices as well as with buying.
Largest stocks (333 in all)
By combined reported value at Q2 2026. Holders are at least counts, among listed positions.
| Stock | Holders | Value | Buyers | Sellers | Holders, 8 quarters |
|---|---|---|---|---|---|
| LLYEli Lilly & Co | 47 | $132bn | 24 | 24 | |
| JNJJohnson & Johnson | 39 | $39.4bn | 18 | 21 | |
| VRTXVertex Pharmaceuticals Inc | 35 | $34.7bn | 21 | 17 | |
| GILDGilead Sciences Inc | 37 | $34.6bn | 22 | 16 | |
| ABBVAbbvie Inc | 39 | $33.5bn | 24 | 16 | |
| MRKMerck & Co Inc | 36 | $29.6bn | 14 | 24 | |
| AZNAstrazeneca PLC | 33 | $29.1bn | 19 | 18 | |
| AMGNAmgen Inc | 31 | $25.2bn | 19 | 13 | |
| ALNYAlnylam Pharmaceuticals Inc | 34 | $16.2bn | 17 | 18 | |
| ABTAbbott Laboratories | 42 | $16.0bn | 23 | 21 | |
| ARGXArgenx Se | 29 | $15.4bn | 16 | 15 | |
| REGNRegeneron Pharmaceuticals | 35 | $11.4bn | 24 | 15 | |
| RVMDRevolution Medicines Inc | 31 | $10.7bn | 16 | 23 | |
| BMYBristol-myers Squibb Co | 34 | $8.4bn | 15 | 23 | |
| MRNAModerna Inc | 27 | $8.1bn | 17 | 17 | |
| GSKGSK PLC | 25 | $7.7bn | 15 | 12 | |
| BIIBBiogen Inc | 29 | $6.2bn | 16 | 17 | |
| PFEPfizer Inc | 34 | $6.0bn | 20 | 16 | |
| IONSIonis Pharmaceuticals Inc | 30 | $5.8bn | 13 | 19 | |
| IDXXIdexx Labs Inc | 36 | $5.6bn | 26 | 16 | |
| BBIOBridgebio Pharma Inc | 35 | $5.4bn | 24 | 15 | |
| ROIVRoivant Sciences LTD | 32 | $5.4bn | 20 | 11 | |
| INSMInsmed Inc | 35 | $5.3bn | 28 | 11 | |
| ASNDAscendis Pharma A | 27 | $4.7bn | 19 | 9 | |
| UTHRUnited Therapeutics Corp Del | 34 | $4.6bn | 19 | 16 |
Managers holding its largest names
Across the 15 largest stocks above at Q2 2026: how many of them each manager lists, and their combined value. A manager can hold others below its listed range.
- Fidelity (FMR LLC)14 of 15 · $84.2bn
- Capital World Investors13 of 15 · $70.4bn
- Capital Research Global Investors11 of 15 · $56.5bn
- T. Rowe Price Associates Inc15 of 15 · $46.4bn
- Wellington Management Group LLP15 of 15 · $45.0bn
- Invesco Ltd14 of 15 · $35.6bn
- Janus Henderson Group Ltd14 of 15 · $17.5bn
- AllianceBernstein LP12 of 15 · $12.2bn
- AQR Capital Management LLC10 of 15 · $7.0bn
- MFS Investment Management9 of 15 · $6.8bn
- Dodge & Cox11 of 15 · $6.7bn
- Neuberger Berman Group LLC11 of 15 · $5.6bn
- Arrowstreet Capital LP11 of 15 · $4.6bn
- Citadel Advisors LLC8 of 15 · $4.3bn
- Two Sigma Investments LP11 of 15 · $3.8bn
- Acadian Asset Management LLC9 of 15 · $3.2bn
- D. E. Shaw & Co.9 of 15 · $3.1bn
- Marshall Wace LLP9 of 15 · $3.0bn
- Farallon Capital Management LLC4 of 15 · $2.8bn
- Man Group PLC13 of 15 · $2.3bn
2.7% of the value at Q2 2026 sits in stocks with no SIC code on file, counted as unclassified rather than placed in a sector.